Key result
Macrophage-specific adiponectin expression reduces atherosclerosis, weight, and inflammation in mice fed a high-fat diet.
Why the study?
Low circulating adiponectin levels are associated with metabolic disorders including obesity, insulin resistance, type 2 diabetes, and cardiovascular disease, but the in vivo metabolic effects of macrophage-specific adiponectin expression are unclear.
Does macrophage-specific adiponectin expression improve metabolic parameters and reduce atherosclerosis in mice fed a high-fat diet?
Does macrophage-specific adiponectin expression improve metabolic parameters and reduce atherosclerosis in mice fed a high-fat diet?
Macrophage-targeted adiponectin expression improves systemic metabolism and reduces atherosclerosis in a preclinical mouse model, suggesting a novel therapeutic strategy for metabolic and cardiovascular diseases.
Hypothesis-generating for macrophage-targeted adiponectin in metabolic disease; leaves open translation and safety in humans.
OBJECTIVE: Adiponectin is one of several important metabolically active cytokines secreted from adipose tissue. Epidemiologic studies have associated low-circulating levels of this adipokine with multiple metabolic disorders including obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. To investigate adiponectin-mediated changes in metabolism in vivo, we generated transgenic mice that specifically express the gene coding for human adiponectin in mouse macrophages using the human scavenger receptor A-I gene enhancer/promoter. METHODS AND RESULTS: Using this transgenic mouse model, we found that adiponectin expression was associated with reduced whole-animal body and fat-pad weight and an improved lipid accumulation in macrophages when these transgenic mice were fed with a high-fat diet. Moreover, these macrophage Ad-TG mice exhibit enhanced whole-body glucose tolerance and insulin sensitivity with reduced proinflammatory cytokines, MCP-1 and TNF-a (both in the serum and in the metabolic active macrophage), adipose tissue, and skeletal muscle under the high-fat diet condition. Additional studies demonstrated that these macrophage adiponectin transgenic animals exhibit reduced macrophage foam cell formation in the arterial wall when these transgenic mice were crossed with an LDL receptor-deficient mouse model and were fed a high-fat diet. CONCLUSIONS: These results suggest that adiponectin expressed in macrophages can physiologically modulate metabolic activities in vivo by improving metabolism in distal tissues. The use of macrophages as carriers for adiponectin, a molecule with antidiabetes, anti-inflammatory, and antiatherogenic properties, provides a novel and unique strategy for studying the mechanisms of adiponectin-mediated alterations in body metabolism in vivo.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2010) studied Obesity, insulin resistance, and atherosclerosis. Macrophage-specific expression of human adiponectin vs. Non-transgenic controls (implied) was evaluated on Body and fat-pad weight, lipid accumulation, glucose tolerance, insulin sensitivity, proinflammatory cytokines, and foam cell formation. Macrophage-specific expression of human adiponectin in mice fed a high-fat diet reduced body and fat-pad weight, improved insulin sensitivity, and decreased inflammation and atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: